Featured Courses

Medical Moments Webinar Series: Applying ADAURA in Practice: Implications for Early Stage EGFRm NSCLC | myCME

AMA PRA Category 1 Credit(s)^TM

This initiative examines the latest ADAURA trial data and the potential utility of adjuvant osimertinib in stage IB-IIIA EGFRm NSCLC.

1,800 Seconds™ in The Expanding Role of PARP Inhibitors in Ovarian Cancer | myCME

AMA PRA Category 1 Credit(s)^TM

A 30-minute video-based online module designed to provide an overview of current evidence on the expanding role of PARP inhibitors in the treatment of ovarian cancer. Dr. Kathleen Moore presents a patient case to provide context for a discussion of emerging data, ongoing clinical trials, and evidence-based strategies to support appropriate selection of patients for treatment with PARP inhibitors.

Promising Options for HER2+ Gastric Cancer Treatment: Focus on Emerging ADCs | myCME

AMA PRA Category 1 Credit(s)^TM

This three-part webcast series explores the burgeoning evidentiary base in support of an expanded role for antibody-drug conjugates in HER2+ gastric cancer.

Treatment Challenges in ALK+ NSCLC: Applying the Latest Clinical Guidance and Evidence to Complex Cases | myCME

AMA PRA Category 1 Credit(s)^TM

4 progressive patient cases that enable clinicians to evaluate and integrate expert guidance when tailoring frontline and subsequent lines of treatment.

Targeted Treatments for Urothelial Cancer

AMA PRA Category 1 Credit(s)^TM, ANCC Contact Hour(s), AANP Contact Hour(s)

This activity will help advanced practitioners who treat patients with UC to know how to select and sequence these treatments.

Exploring Selection + Sequencing: A Multidisciplinary Tumor Board Discussion on Treatment Options for Patients With Advanced HCC | myCME

AMA PRA Category 1 Credit(s)^TM, CNE Contact Hour(s), AANP Contact Hour(s)

The number of available systemic treatment options for advanced hepatocellular carcinoma (HCC) has rapidly increased over the last 3 years, providing new hope for patients but also new challenges in treatment selection and sequencing for healthcare professionals (HCPs). To help address these challenges, this 60-minute activity will allow you to “listen in” as a multidisciplinary team of experts discuss a patient case in a style similar to a tumor board meeting.

Individualizing Treatment Strategies in Ovarian Cancer | myCME

AMA PRA Category 1 Credit(s)^TM, AAPA Category I CME credit

The landscape of maintenance treatment options for ovarian cancer has been rapidly evolving as new clinical trial data emerge. In this 30-minute, interactive activity, Drs Birrer and Matulonis will examine relevant data with regard to genetic and histologic markers that may guide individualization of therapy. Expert insights on effectively preventing and managing adverse events associated with maintenance therapy for ovarian cancer will be reviewed.

Molecular Tumor Board Series 2020: Part III | myCME

AMA PRA Category 1 Credit(s)^TM

Part III of four cases featuring a multidisciplinary molecular tumor board discussing cancer patient cases.

Immunotherapy for the Treatment of Melanoma and Lung Cancer | myCME

CNE Contact Hour(s)

This program will outline the necessary and unique skill sets of the nurse navigator; which includes a thorough knowledge of lung cancer and melanoma biology, treatments, and treatment side effects; the ability to address psychosocial issues; and expertise in accessing and navigating the healthcare system on behalf of their patients.

One and All: Navigating Multiple Tumor Types | myCME

CNE Contact Hour(s)

This activity will provide ONNs best practices on the successful implementation of the nurse navigator role in the management of patients with multiple types of tumors.

Closing Disparity Gap and Optimizing HCC Care in Hispanic Community | myCME

AMA PRA Category 1 Credit(s)^TM, ANCC Contact Hour(s)

Significant race and ethnicity-specific disparities in HCC remain, particularly among Hispanics, who are more likely to present late and less likely to receive any HCC-directed treatment. To optimize care, clinicians must be vigilant about recognizing and addressing these disparities in care; and must also ensure and work towards Hispanic patients with HCC benefiting from the growing range of HCC management options.

Tenosynovial Giant Cell Tumors: New Treatments for a Distinct and Often Misdiagnosed Disease | myCME

AMA PRA Category 1 Credit(s)^TM, ANCC Contact Hour(s), CE for Pharmacists

The current standard of care for localized tenosynovial giant cell tumors (TGCT) is surgical resection. However, diffuse disease often has more extensive involvement and a poorer likelihood of successful cure with surgery, higher risk of recurrence, and substantial morbidity and lower quality of life.